NASDAQ · BDTX
Healthcare · Biotechnology
$1.81
Up+$0.06 (+3.43%)
Updated Nov 4, 2026, 12:57 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BDTX
1M range · 0 trading sessions · Daily adjusted prices
BDTX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BDTX.
Company
Market Activity
Research & News
BDTX research
Company profile and research snapshot.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 29, 2026 | BTIG | Buy | — |
| Mar 17, 2026 | Wedbush | Outperform | — |
| Jan 16, 2026 | Piper Sandler | Overweight | — |
| Dec 4, 2025 | Guggenheim | Neutral | — |
No generated briefing is available yet.
Benzinga · May 7, 2026
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.03) by 433.33 percent. This is a 116.33 percent decrease over earnings of $0.98
Finnhub · May 7, 2026
CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Black Diamond Therapeutics, Inc. on Thursday reported a first-quarter loss of $9 million, after reporting a profit in the same period a year earlier. The...
Finnhub · May 7, 2026
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase...
Benzinga · Apr 29, 2026
BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDTX.
